Evaluating the effect of Dapagliflozin on Proteinuria in Type 2 Diabetic Patients.

Phase 4

• Conditions: Type 2 Diabetes Mellitus; Kidney disease; Metabolic and Endocrine - Diabetes; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12624000033549
• Lead Sponsor: MTI Lady Reading Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-01-15
• Last Update Posted: 29 January 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 516

Inclusion Criteria

1. Age more than 16 years or older.
2. Gender: Any
3. Patients diagnosed as having type 2 diabetes mellitus (Fasting blood glucose of >126 mg/dl or HbA1C > 6.5 %) who are having proteinuria of more than 150mg / 24 hours already on maximum tolerated dose of Angiotensin Converting Enzyme Inhibitors (ACEi) or Angiotensin receptor Blockers (ARBs).

Exclusion Criteria

1.Patients with type 1 diabetes mellitus (SGLT2 inhibitors may precipitate Diabetic Ketoacidosis)
2. Pregnancy (SGLT2 inhibitors not licensed) and
3. Cancer.
4.Patients already on SGLT2 inhibitors
5.Patients on treatments which may impair glucose metabolism, such as immunosuppressant/immunomodulators and systemic or local steroid therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified